Xtx Topco LTD Allogene Therapeutics, Inc. Transaction History

Xtx Topco LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.92 - $5.63 $1,106 - $2,133	379 Added 1.07%	35,765 $159,000
Q4 2023 Feb 13, 2024	SELL	$2.28 - $3.5 $88,017 - $135,114	-38,604 Reduced 52.17%	35,386 $113,000
Q3 2023 Nov 13, 2023	BUY	$3.17 - $5.96 $89,264 - $167,827	28,159 Added 61.44%	73,990 $234,000
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $1,173 - $1,745	259 Added 0.57%	45,831 $227,000
Q1 2023 May 12, 2023	SELL	$4.92 - $8.21 $350,618 - $585,077	-71,264 Reduced 60.99%	45,572 $225,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $439,450 - $868,735	78,194 Added 202.35%	116,836 $734,000
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $398,785 - $667,733	38,642 New	38,642 $417,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.